Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04724070

PRecision Oncology CUhk pRogrammE (PRO-CURE)

The main aim of this project is to establish an innovative model of a comprehensive precision oncology platform to help individualizing drug therapy for patients with advanced cancers at The Chinese University of Hong Kong. The other objectives include to optimize the genomic matching and access of patients with unique cancer subtypes to the relevant clinical trials of novel therapies, and to construct a personalized drug screening platform for individuals using novel cancer models established from patient-derived cancer cells and tissues. Other objectives include to investigate the utility and feasibility of genomic sequencing using circulating tumor DNA(ctDNA), and to establish a biobank of tumor tissues derived from patients with unique cancer subtypes.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Gastrointestinal Cancers Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasms Neoplasms by Site

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The Chinese University of Hong Kong

Hong Kong

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be aged between 18 to 75 years
  • Must have ECOG performance status of 0 to 1
  • Must have histologically/cytologically confirmed cancers of certain subtype
  • Medically fit patients who would need systemic therapy as part of their oncological treatment in any one or more of the following oncological setting(s): palliative, neoadjuvant, adjuvant, concurrent with radiotherapy. This includes patients who have limited systemic therapeutic options for their cancers and are candidates for clinical trials.
  • Able to give written informed consent
  • Willing to have blood samples taken.
  • Availability of an archived paraffin-embedded tumor block

Exclusion criteria

  • Patients who refuse or are medically unfit for systemic therapy for their cancer
  • Patients with more than one invasive cancers diagnosed over the last FIVE years.
  • Patients without measurable tumor lesions on radiological imaging
  • Patients who are unable to give written informed consent.

Treatment and study plan

NGS, PDO/PDX establishment

Genetic

Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.

Primary outcomes

  1. Establishment of an innovative model of a comprehensive precision oncology platform

    Time frame: 4 years

  2. Construction of a personalized drug screening platform for individuals using novel cancer models established from patient-derived cancer cells and tissues.

    Time frame: 4 years

Secondary outcomes

  1. Describe the prevalence of actionable genomic aberrations in patients with advanced cancers in Hong Kong

    Time frame: 4 years

Sponsors and collaborators

Lead sponsor

Brigette Ma

Other

Registry information

Official study title

Comprehensive Precision Oncology Program at The Chinese University of Hong Kong

Important dates

Study start
2019
Primary completion
2026
Study completion
2027
First posted
Jan 26, 2021
Registry last updated
Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.